Dr.
Craig B. Thompson resigned Tuesday from the board of the drugmaker
Merck and another public company as he tries to address staff turmoil in
the wake of a crisis over conflicts of interest.
by Katie Thomas, The New York Times, and Charles Ornstein, ProPublica
This article was produced in partnership with The New York Times.
Dr. Craig B. Thompson, the chief executive of Memorial Sloan
Kettering Cancer Center, said Tuesday that he would resign his seats on
the boards of drugmaker Merck and another public company, the latest
fallout from a growing institutional reckoning over relationships
between cancer center leaders and for-profit health care companies.
Thompson has served on the board of Merck, the maker of the
blockbuster cancer drug Keytruda, since 2008. He has been on the board
of Charles River Laboratories, a publicly traded company that assists
research in early drug development, since 2013.
Thompson received $300,000 in compensation from Merck in 2017, according to company financial filings. He was paid $70,000 in cash by Charles River in 2017, plus $215,050 in stock.
Click here for the full announcement.
No comments:
Post a Comment